Thrombolytic therapy. From myocardial to cerebral infarction

  • Candelise L. 
  • Roncaglioni C. 
  • Aritzu E. 
  • Ciccone A. 
  • Maggioni A. P. 
  • the MAST-I Group
Review

Abstract

Thrombolysis is proposed for the acute treatment of cerebral infarction as it is able to recanalize occluded arteries and thus potentially restore normal perfusion of the cerebral parenchyma, but the results concerning the efficacy of this treatment are still inconclusive. However, it has been fully demonstrated that thrombolytic treatment, leads to a significant reduction in mortality, in patients with acute myocardial infarction.

Data from all of the pilot studies using SK or rPA treatment in acute stroke are described in this review, which underlines the incidence of hemorrhagic transformation (hemorrhagic infart and parenchymal hematoma) and its possible correlation to clinical worsening.

Pharmacological, experimental and clinical studies encourage the carrying out of large-scale clinical trials using thrombolytics in patients with acute cerebral infarction.

Significant data relating to ongoing controlled clinical trials will be available in the near future; only after the analysis of these results will it be possible to confirm the efficacy of thrombolytics in acute stroke.

Key Words

Acute cerebral stroke Trombolytic therapy Cerebral recanalization Myocardial infarction 

Sommario

La trombolisi è stata proposta nella fase acuta dell'infarto cerebrale quale terapia potenzialmente in grado di operare una ricanalizzazione arteriosa ed una conseguente riperfusione dell'area ischemica; ad oggi, però, i risultati degli studi eseguiti non permettono di provarne la reale efficacia. È già stato invece ampiamente dimostrato come il trattamento trombolitico determini una significantiva riduzione della mortalità nei pazienti colpiti da infarto miocardico acuto.

In questa revisione vengono esaminati i risultati degli studi pilota condotti su pazienti con ictus acuto trattati con Streptokinasi o tPA, mettendo in luce l'incidenza delle trasformazioni emorragiche (infarto emorragico ed ematoma intraparenchimale) correlate all'evoluzione clinica.

Gli studi farmacologici, sperimentali e clinici incoraggiano l'esecuzione di ampi studi con l'utilizzo della trombolisi anche in pazienti con infarto cerebrale.

Prossimamente conosceremo i risultati degli studi in via di completamento: solo l'analisi di quei dati ci permetterà di confermare la reale efficacia di questo trattamento.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Abe T., Terashi A., Tohgi H. et al.:Clinical efficacy of intravenous administration of SM-9527 (tPA) in cerebral thrombosis. Clin. Eval., 18: 36–69, 1990.Google Scholar
  2. [2]
    Anderson V., Willerson J.T. Thrombolysis in acute myocardial infarction. Curr. Concepts, 329, 10: 703–709, 1993.Google Scholar
  3. [3]
    Anglo-Scandinavian Study of Early thrombolysis (ASSET):Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet, ii: 525–530, 1988.Google Scholar
  4. [4]
    Ardissino D., Barberis P., De Servi S. et al.:Recombinant tissue-type plasminogen activator followed by heparin compared with heparin alone for refractory unstable angina pectoris. Am. J. Cadiol. 66: 910–914, 1990.Google Scholar
  5. [5]
    Baird A.E., Donnan G.A., Austin M.C., Fitt G.J., McKay W.J.:HMPAO SPECT measures reperfusion after thrombolytic therapy in acute stroke. In: Del Zoppo G.J., Mori E., Hacke W. (Eds.):Thrombolytic therapy in acute ischemic stroke, Springer-Verlag Berlin Heidelberg, pp. 301–303, 1993.Google Scholar
  6. [6]
    Bamford J., Sandercock P., Dennis M., Burn J., Warlow C.:A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981-86-2: incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J. Neurol. Neurosurg. Psychiatry, 53: 16–22, 1990.PubMedGoogle Scholar
  7. [7]
    Bar F., Vermeer F., Verheugt F., Col J. et al.:Thrombolysis in patients with unstable angina improves the angiographic but not the clinical outcome. Results of UNASEM, a multicenter, randomised, placebo-controlled, clinical trial with Anistreplase. Circulation, 86: 131–137, 1992.PubMedGoogle Scholar
  8. [8]
    Baron J.C.:Pathophysiology of acute cerebral ischemia: PET studies in humans. Cerebrovascular Dis 1 (suppl.): 22–31, 1991.Google Scholar
  9. [9]
    Bednar M.M., Mc Auliffe T., Raymond S., Gross C.:Tissue plasminogen activator reduces brain injury in a rabbit model of thromboembolic stroke. Stroke, 21: 1705–1709, 1990.PubMedGoogle Scholar
  10. [10]
    Benes V., Zabramski J.M., Boston M., Puca A., Spetzler R.F.:Effect of intra-arterial antifibrinolytic agents on autologous arterial emboli in the cerebral circulation of rabbits. Stroke, 21: 1594–1599, 1990.PubMedGoogle Scholar
  11. [11]
    Berg-Dammer E., Topper R., Mobius E., Nahser H.C., Kuhne D.:Local thrombolytic therapy of thromboembolic occlusion of the middle cerebral artery. In:Proceedings of the Second International Conference on Acute Stroke. Geneva, 1–2, p. 62, 1991 (abstract).Google Scholar
  12. [12]
    Biller J., Love B.B., Marsh E.E. et al.Spontaneous improvement after acute ischemic stroke. A pilot study. Stroke, 21: 1008–1012, 1990.Google Scholar
  13. [13]
    Bouschery R.: Fibrinolytische Behandlung der Hirnembolic mit Streptokinase. Med. Welt., 43: 2588, 1967.PubMedGoogle Scholar
  14. [14]
    Braunwald E.:The open-artery theory is alive and well again. N. Engl. J. Med. Nov. 25: 1650–1652, 1993.Google Scholar
  15. [15]
    Brott T.:Thrombolytic therapy for stroke.Cerebrovascular and brain metabolism reviews, 3: 91–113, 1991.PubMedGoogle Scholar
  16. [16]
    Brott T.G., Haley E.C., Levy D.E. et al.:Urgent therapy for stroke. Part. I Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke, 23: 632–640, 1992.PubMedGoogle Scholar
  17. [17]
    Brucker A.B., Potuschak H., Laich E., Trenkler J., Bohm-Jurkovic H., Deisenhammer E.:Relation of thrombolytic reperfusion and of collateral circulation to outcome in patients suffering cerebral main artery occlusion. In Del Zoppo G.J., Mori E., Hacke W. (Eds.).Thrombolytic therapy in acute ischemic stroke II. Springer-Verlag Berlin Heidelberg, 288–291, 1993.Google Scholar
  18. [18]
    Bruckmann H., Ferbert A.:Putminal hemorrhage after recanalization of an embolic MCA occlusion treated with tissue plasminogen activator. Neuroradiology, 31: 95–97, 1989.PubMedGoogle Scholar
  19. [19]
    Buteux G., Jabault V., Suisse A.:Local recombinant tissue plasminogen activator to clear cerebral artery thrombosis developing soon after surgery. Lancet, 12: 1143–1144, 1988.Google Scholar
  20. [20]
    Candelise L.:New treatments for acute ischemic stroke. In: Adams H.P. Jr. (Ed.),Handbook of Cerebrovascular Diseases. M. Dekker, pp. 415–432, 1993.Google Scholar
  21. [21]
    Carter L.P., Guthkelch A.N., Orozco J., Temeltas O.:Influence of tissue plasminogen activator and heparin on cerebral ischemia in a rabbit model. Stroke, 23: 883–888, 1992.PubMedGoogle Scholar
  22. [22]
    Chamberlain D.A.:Unanswered questions in thrombolysis. Am. J. Cardiol. 63: 34A-40A, 1989.Google Scholar
  23. [23]
    Chesebro J.H., Knatterud G., Roberts R. et al.:Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circ. 6, 1: 142–154, 1987.Google Scholar
  24. [24]
    Ciccone A., Candelise L.:Brain hemorrhage after thrombolysis: a meta-analysis of animal stroke models (submitted for publication).Google Scholar
  25. [25]
    Clark W., Madden K., Lyden P.D., Zivin A.:Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits. Stroke, 22: 872–876, 1991.PubMedGoogle Scholar
  26. [26]
    De Ley G., Weyne J., Demeester G. et al.:Experimental thromboembolic stroke studied by positron emission tomography: immediate versus delayed reperfusion by fibrinolysis. J. Cereb. Blood Flow Metab., 8: 539–545, 1988.PubMedGoogle Scholar
  27. [27]
    Del Zoppo G.J., Poeck K., Pessin M.S. et al.:Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann. Neurol. 32: 78–86, 1992.PubMedGoogle Scholar
  28. [28]
    Del Zoppo G.J., Copeland B.R., Anderchek K., Hache W., Koziol J.A.:Hemorrhagic transformation following tissue plasminogen activator in experimental cerebral infarction. Stroke, 21: 596–601, 1990.PubMedGoogle Scholar
  29. [29]
    Del Zoppo G.J., Copeland B.R., Walz T.A., Zyroff J., Plow E.F., Harker L.A.:The beneficial effect of intracarotid urokinase on acute stroke in a baboon model. Stroke, 17: 638–643, 1986.PubMedGoogle Scholar
  30. [30]
    Del Zoppo G.J., Ferbert A., Otis S. et al.:Local intraarterial fibrinolytic therapy in acute carotid territory stroke. A pilot study. Stroke, 19: 307–313, 1988.Google Scholar
  31. [31]
    Del Zoppo G.J., Pessin M., Mori E., Hacke W.:Thrombolytic intervention in acute thrombotic and embolic stroke. Seminars in Neurology, Vol. II; 4: 368–384, 1991.Google Scholar
  32. [32]
    Del Zoppo G.J., Poeck K., Pessin M.S. et al.:Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann. Neurol. 32: 78–86, 1992.PubMedGoogle Scholar
  33. [33]
    Donnan G.A., Davis S.M., Chambers B.R. et al.:Trials of streptokinase in severe acute ischaemic stroke (letter). Lancet, i, 345: 578–579, 1995.Google Scholar
  34. [34]
    ECGS (European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction):Streptokinase in acute myocardial infarction. N. Engl. J. Med. 301: 797–802, 1979.Google Scholar
  35. [35]
    EMERAS (Estudio Multicéntrico Estreptoquinasa Republicas de América del Sud) Collaborative Group:Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet, 342: 767–772, 1993.Google Scholar
  36. [36]
    Falk E.:Coronary thrombosis: pathogenesis and clinical manifestations. Am. J. Cardiol. 68: 288–358, 1991.PubMedGoogle Scholar
  37. [37]
    Fieschi C., Argentino C., Lenzi G.L. et al.:Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J. Neurol. Sci. 91: 311–322, 1989.PubMedGoogle Scholar
  38. [38]
    Foresti A., Abrosini F., Gentile G., Repetto S., Lotto A.:Thrombolytic therapy in unstable angina: effects of short term high dose intravenous urokinase. Thromb. Haem., 58: 63, 1987 (abstract).Google Scholar
  39. [39]
    Freeman M.R. et al.:Thrombolysis in unstable angina: randomised double-blind trial of tPA and placebo. Circulation, 85: 150–157, 1992.PubMedGoogle Scholar
  40. [40]
    Frink R.J., Ostrach L.H.:Streptokinase in the treatment of an acute cerebral embolus. A case report. Angiology, 41: 66–69, 1990.PubMedGoogle Scholar
  41. [41]
    FTT Collaborative Group:Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet, 343: 311–322, 1994.Google Scholar
  42. [42]
    Fujiwara H., Onodera T., Tanaka M. et al.:A clinicopathologic study of patients with hemorrhagic myocardial infarction treated with selective coronary thrombolysis with urokinase. Circulation, 4: 749–757, 1986.Google Scholar
  43. [43]
    Gold H.K., Johns J.A., Leinbach R.C. et al.:A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris. Circulation, 75: 1192–1199, 1987.PubMedGoogle Scholar
  44. [44]
    Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico:GISS1–2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet, 336: 65–71, 1990.Google Scholar
  45. [45]
    Gruppo Italiano per lo Studio della Streptokinasi nell'Infarto Miocardico (GISSI):Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet, i: 397–402, 1986.Google Scholar
  46. [46]
    Guerci A.D., Gerstenblith G., Brinker J.A., et al.:A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N. Engl. J. Med. 317: 1613–1618, 1987.PubMedGoogle Scholar
  47. [47]
    Hacke W., Zeumer H., Ferbert A., Bruckmann H., Del Zoppo G.J.:Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebro-basilar occlusive disease. Stroke, 19: 1216–1222, 1988.Google Scholar
  48. [48]
    Hacke W.:Thrombolysis stroke and embolus type. In: Del Zoppo G.J., Mori E., Hacke W. (Eds.)Thrombolytic Therapy in Acute Ischemic Stroke II. Springer-Verlag, pp. 153–159, 1993.Google Scholar
  49. [49]
    Haley E.C., Brott T.G., Sheppard G.L. et al.Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke, 24: 1000–1004, 1993.PubMedGoogle Scholar
  50. [50]
    Haley E.C., Levy D.E., Brott T.G., et al.:Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91–180 minutes from onset. Stroke, 23: 641–645, 1992.PubMedGoogle Scholar
  51. [51]
    Hall G.H.:Bolus streptokinase after myocardial infarction. Lancet ii: 96–97, 1987.Google Scholar
  52. [52]
    Henderscheé D., Limburg M., Hijdra A., Koster P.A.:Recombinant tissue plasminogen activator in two patients with basilar artery occlusion. J. Neurol. Neurosurg Psychiatry, 54: 71–73, 1991.PubMedGoogle Scholar
  53. [53]
    Hennerici M., Hacke W., von Kummer R., Hornig C., Zangemeister W.:Intravenous tissue plasminogen activator for the treatment of acute thromboembolic ischemia. Cerebrovasc. Dis. 1 (suppl. 1): 124–128, 1991.Google Scholar
  54. [54]
    Henze T.H.:Lysis of basilar artery occlusion with tissue plasminogen activator. Lancet, ii, 12: 1391, 1987.Google Scholar
  55. [55]
    Hommel M., Boissel J.P., Cornu C. et al.:Termination of trial of streptokinase in severe acute ischaemic stroke (letter). Lancet, 345: 57, 1995.Google Scholar
  56. [56]
    Hossmann K.A.:Viability thresholds and the penumbra of focal ischemia. Ann. Neurol. 36: 557–565, 1994.PubMedGoogle Scholar
  57. [57]
    ISIS (International Studies of Infarct Survival) Pilot Study Investigators:Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. Eur. Heart. J., 8: 634–642, 1987.Google Scholar
  58. [58]
    ISIS 2 (Second International Study of Infarct Survival) Collaborative Group:Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, ii: 349–360, 1988.Google Scholar
  59. [59]
    Jaegere P.P. de, Arnold A.A., Balk A.H., Simoons M.L.:Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors. J. Am. Coll. Cardiol. 19: 289–294, 1992.PubMedGoogle Scholar
  60. [60]
    Jafar J.J., Tan W.S., Crowell R.M.:Tissue plasminogen activator thrombolysis of a middle cerebral artery embolus in a patient with an arteriovenous malformation. J. Neurosurg. 74: 808–812, 1991.PubMedGoogle Scholar
  61. [61]
    Karisson J. E., Berglund U., Bjokholm A. et al.:Thrombolysis with recombinant human tissue type plasminogen activator during instability in coronary heart disease-effect on myocardial ischaemia and need for coronary revascularisation (TRIC study) (In press).Google Scholar
  62. [62]
    Karnik R., Stelzer P., Slany J.:Transcranial doppler sonography monitoring of local intra-arterial thrombolysis in acute occlusion of the middle cereral artery. Stroke, 23: 284–287, 1992.PubMedGoogle Scholar
  63. [63]
    Kase C.S., Pessin M.S., Zivin J.A. et al.:Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. Am. J. Med. 4: 384–390, 1992.Google Scholar
  64. [64]
    Kassmeyer H., Widock W.: Thrombolyse bei Verschluss der Arteria Carotis Interna. Med-Welt, 31: 1737, 1965.PubMedGoogle Scholar
  65. [65]
    Kennedy J.W., Martin G.V., Davis K.B. et al.:The Western Washington intravenous streptokinase in acute myocardial infarction randomized trial. Circulation, 77: 345–352, 1988.PubMedGoogle Scholar
  66. [66]
    Kittner S.J., Sharkness C.M., Sloan M.A. et al.:Infarcts with a cardiac source of embolism in the NINDS Stroke Data Bank: Neurologic examination. Neurology, 42: 299–302, 1992.PubMedGoogle Scholar
  67. [67]
    Koudstaal P.J., Stibbe J., Vermeulen M.:Fatal ischaemic brain oedema after early thrombolysis with tissue plasminogen activator in acute stroke. Br. Med. J. 297: 1571–1574, 1988.Google Scholar
  68. [68]
    LATE Study Group:Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet, 342: 759–766, 1993.Google Scholar
  69. [69]
    Lau J., Antman E.M., Jemenez-Silva J., Kupelnick B., Mosteller F., Chalmers T.C.:Cumulative meta-analysis of therapeutic trials for myocardial infarction. N. Engl. J. Med. 327: 248–254, 1992.PubMedGoogle Scholar
  70. [70]
    Lincoff A.M., Topol E.J.:Illusion of reperfusion — Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation, 87: 1792–1805, 1993.Google Scholar
  71. [71]
    Lyden P.D., Madden K.P., Clark W.M., Sasse K.C., Zivin J.A.:Incidence of cerebral hemorrhage after antifibronolytic treatment for embolic stroke in rabbits. Stroke, 21: 1589–1593, 1990.PubMedGoogle Scholar
  72. [72]
    Lyden P.D., Zivin J.A., Clark W.A. et al.:Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits. Neurology, 39: 703–708, 1989.PubMedGoogle Scholar
  73. [73]
    Lyden P.D., Zivin J.A.:Hemorrhage transformation after cerebral ischemia: mechanism and incidence. Cerebrovasc. Brain Metab. Reviews, 5: 1–16, 1993.Google Scholar
  74. [74]
    Maggioni A.P., Franzosi M.G., Sartoro E., et al.:Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and the International Study Group: The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombolytic treatment. N. Engl. J. Med. 327: 1–6, 1992.PubMedGoogle Scholar
  75. [75]
    Magnani B. for the PAIMS Investigators:Plasminogen Activator Italian Multicenter Study (PAIMS): Comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction. J. Am. Coll. Cardiol. 13: 19–26, 1989.PubMedGoogle Scholar
  76. [76]
    Maisa D., Theron J., Pelouze G.A., et al.:Local fibrinolytic therapy in ischemic carotid pathology. Ann. Vasc. Surg. 2: 205–214, 1988.PubMedGoogle Scholar
  77. [77]
    Malinovsky N.N., Kozlow V.A.:Embolism of the cerebral arteries. In: Malinovsky N.N., Kozlow V.A. (Eds.),Anticoagulant and Thrombolytic Therapy in Surgery. St. Luis, CV Mosby Company, pp. 239–250, 1979.Google Scholar
  78. [78]
    Marchal G., Serrati C., Rioux P. et al.:PET imaging of cerebral perfusion and oxygen consumption in acute ischaemic stroke: relation to outcome. Lancet, 341: 925–927, 1993.PubMedGoogle Scholar
  79. [79]
    Marder V.J.:Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy. Am. J. Med. 83 (2A): 15–19, 1987.Google Scholar
  80. [80]
    Meyer G.S., Gilroy J., Barnhart M.I. et al.:Anticoagulants plus streptokinase therapy in progressive stroke. JAMA, 189: 373, 1964.PubMedGoogle Scholar
  81. [81]
    Minematsu K., Yamaguchi T., Omae R.:“Spectacular shrinking deficit”: Rapid recovery from a major hemispheric syndrome by migration of an embolus. Neurology, 42: 157–162, 1992.PubMedGoogle Scholar
  82. [82]
    Mobius E., Berg-Dammer E., Kuhne D., Nahser H.C.:Local thrombolytic therapy in acute basilar artery occlusion: experience with 18 patients. In: Hacke W., Del Zoppo G.J., Hirschberg (Eds.),Thrombolytic Therapy in Acute Ischemic Stroke. Berlin Heidelberg, Springer Verlag, pp. 213–215, 1991.Google Scholar
  83. [83]
    Mori E., Yoneda Y., Tabuchi M. et al.:Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology, 42: 976:998, 1992.PubMedGoogle Scholar
  84. [84]
    National Heart Foundation of Australia Coronary Thrombolysis Group:Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. Lancet, i: 203–207, 1988.Google Scholar
  85. [85]
    Nenci G.G., Gresele P., Taramelli M., Agnelli G., Signorini E.:Thrombolytic therapy for thromboembolism of the vertebro-basilar artery. Angiology, 34: 561–571, 1983.PubMedGoogle Scholar
  86. [86]
    O'Rourke M., Baron D., Keogh A. et al.:Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. Circ. 77: 1311–1315, 1988.Google Scholar
  87. [87]
    Okada Y., Sadoshima S., Fujischima M.:Thrombolytic therapy for acute cerebral embolism: its efficacy and the incidence of hemorrhagic transformation. J. Neurol. 238: 121, 1991.Google Scholar
  88. [88]
    Okada Y., Sadoshima S., Nakane H., Utsunomiya H., Fujishima M.:Early computed tomographic findings for thrombolytic therapy in patients with acute brain embolism. Stroke, 23: 20–23, 1992.PubMedGoogle Scholar
  89. [89]
    Olson H.G., Butman S.M., Piters K.M. et al.:A randomized controlled trial of intravenous streptokinase in evolving acute myocardial infarction. Am. Heart. J, 11: 1021–1029, 1986.Google Scholar
  90. [90]
    Otomo E., Toghi H., Hirai S. et al.:Clinical efficacy of AK-124 (tissue plasminogen activator) in the treatment of cerebral thrombosis: study by means of multicenter double blind comparison with urokinase. Uakuri To Chiryo, 16: 3775–3821, 1988.Google Scholar
  91. [91]
    Overgaard K., Sperling B., Boysen G. et al.:Thrombolytic therapy in acute ischemic stroke: A Danish pilot study. Stroke, 24: 1439–1446, 1993.PubMedGoogle Scholar
  92. [92]
    Phillips D.A., Fisher M., Davis M.A., Smith T.W., Pang R.H.L.:Delayed treatment with a tPA analogue and streptokinase in a rabbit embolic stroke model. Stroke, 21: 602–605, 1990.PubMedGoogle Scholar
  93. [93]
    Phillips D.A., Fisher M., Smith T.W., Davis M.A., Pang R.H.L.:The effects of a new tissue plasminogen activator analogue, Fb-Fb-CF, on cerebral reperfusion in a rabbit embolic stroke model. Ann. Neurol. 25: 281–285, 1989.PubMedGoogle Scholar
  94. [94]
    Primi Trial Study Group:Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet, i: 863–869, 1989.Google Scholar
  95. [95]
    Ringelstein E.B., Biniek R., Weiller C., Ammeling B., Nolte P.N., Thron A:Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology, 42: 289–298, 1992.PubMedGoogle Scholar
  96. [96]
    Ringelstein E.B., Otis S.M., Spaar-Kahlscheuer B., Niggemeyer E.:Transcranial Doppler sonography. Anatomical landmarks and normal velocity values. Ultrasound Med. Biol. 16: 745–761, 1990.PubMedGoogle Scholar
  97. [97]
    Roberts M.J.D. et al.:Thrombolytic therapy for unstable angina — a double blind placebo-controlled trial with alteplase. Eur. Heart J., 12: 134, 1991 (abstract).PubMedGoogle Scholar
  98. [98]
    Sabia P.J., Powers E.R., Ragosta M., Sarembock I.J., Burwell L.R., Kaul S.:An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N. Engl. J. Med., 327: 1825–1831, 1992.PubMedGoogle Scholar
  99. [99]
    Sansa M., Cemigliaro C., Campi A., Simonetti I.:Effects of urokinase and heparin on minimal cross-sectional area of the culprit narrowing in unstable angina pectoris. Am. J. Cardiol., 68: 451–456, 1991.PubMedGoogle Scholar
  100. [100]
    Saran R.K., Bhandari K., Narain V.S. et al.:Intravenous streptokinase in the management of a subset of patients with unstable angina: a randomised controlled trial. Int. J. Cardiol. 28: 209–213, 1990.PubMedGoogle Scholar
  101. [101]
    Simoons M.L., Maggioni A.P., Knatterud G. et al.:Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. Lancet, 342: 1523–28, 1993.PubMedGoogle Scholar
  102. [102]
    Slivka A., Pulsinelli W.:Hemorrhagic complications of thrombolytic therapy in experimental stroke. Stroke, 18: 1148–1156, 1987.PubMedGoogle Scholar
  103. [103]
    Terashi A., Hobayashi Y., Katayama Y., Inamura K., Kazama M., Abe T.:Clinical effects and basic studies of thrombolytic therapy on cerebral thrombosis. Semin Thromb Hemost, 16: 236–241, 1990.PubMedGoogle Scholar
  104. [104]
    The GUSTO investigators:An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 329: 673–682, 1993.Google Scholar
  105. [105]
    The International Study Group:In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparing. Lancet, 336: 71–75, 1990.Google Scholar
  106. [106]
    The ISAM Study Group:A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity and infart size at 21 days. N. Engl. J. Med. 314: 1465–1471, 1986.Google Scholar
  107. [107]
    The Thrombolysis Early in Acute Heart Attack Trial Study Group:Very early thrombolytic therapy in suspected acute myocardial infarction. Am. J. Cardiol., 65: 401–407, 1990.Google Scholar
  108. [108]
    Theron J., Courteoux P., Casasco A. et al.:Local intraarterial fibrinolysis in the carotid territory. A J N R, 10: 753–765, 1989.Google Scholar
  109. [109]
    Third International Study of Infarct Survival. Collaborative Group:ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin alone among 41,299 cases of suspected acute myocardial infarction. Lancet, 339: 753–770, 1992.Google Scholar
  110. [110]
    TIMI-3 trial.Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non Q-wave myocardial infarction. Circulation, 89: 1545–1556, 1994.Google Scholar
  111. [111]
    Topol E.J., Morris D.C., Smalling R.W. et al.:A multicenter randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (Activase) in acute myocardial infarction. J. Am. Coll. Cardiol., 9: 1205–1213, 1987.PubMedGoogle Scholar
  112. [112]
    Topol E.J., Nicklas J.M., Kander N.H. et al.:Coronary revascularization unstable angina pectoris: results of randomized double-blind placebo-controlled trial. Am. J. Cardiol. 62: 368–371, 1988.PubMedGoogle Scholar
  113. [113]
    Turrin M., Martinelli S., Grazioli E.:Fibrinolytic therapy in acute ischemic stroke: description of a case of carotid thrombolysis with rt-PA intravenous infusion. J. Neurol., 238: 126, 1991 (abstract).Google Scholar
  114. [114]
    Van de Werf F., Arnold A.E.R. for the European Cooperative Study Group for recombinant tissue-type plasminogen activator:Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. Br. Med. J. 297: 1374–1379, 1988.Google Scholar
  115. [115]
    Van der Brand M., Van Zijl A., Geuskens R., de Feyter P.J., Serruys P.W., Simoons M.:A randomised double-blind placebo controlled trial in patients with refractory unstable angina and subsequent angioplasty. European Heart Journal, 12: 1208–1214, 1991.PubMedGoogle Scholar
  116. [116]
    Verstraete M., Bernard R., Bory M. et al.:Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet, i: 842–847, 1985.Google Scholar
  117. [117]
    Verstraete M., Bleifeld W., Brower R.W. et al.:Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet, ii: 965–969, 1985.Google Scholar
  118. [118]
    Von Belz G.G.: Fibrinolytische Therapie. Erfahrungsbericht uber fung jahre. Munch Med. Wschr, 111: 2357, 1969.PubMedGoogle Scholar
  119. [119]
    von Kummer R., Hacke W.:Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke, 23: 646–652, 1992.PubMedGoogle Scholar
  120. [120]
    Von Stricker E., Schmutzler R.: Erfolgreiche thrombolyse eines arteriellen cerebralen Gefa-Bverschlusses. Schw Med. Woch, 18: 615–617, 1964.Google Scholar
  121. [121]
    Wardlaw J.M., Warlow C.P.:Thrombolysis in acute ischemic stroke: Does it work? Stroke, 23: 1826–1839, 1992.PubMedGoogle Scholar
  122. [122]
    White H.D., Norris R.M., Brown M.A. et al.:Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N. Engl. J. Med. 317: 850–855, 1987.PubMedGoogle Scholar
  123. [123]
    White H.D., Rivers J.T., Maslowski A.H. et al.:Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N. Engl. J. Med. 320: 817–821, 1989.PubMedGoogle Scholar
  124. [124]
    Wildemann B., Hutschenreuter M., von Kummer R.:Infusion of recombinant tissue plasminogen activator for treatment of basilar artery occlusion. Stroke, 21, 10: 1513–1514, 1990.PubMedGoogle Scholar
  125. [125]
    Williams D.O., Topol E.J., Claiff R.M. et al.:Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled randomized trial. Circulation, 82: 376–383, 1990.PubMedGoogle Scholar
  126. [126]
    Yamaguchi T., Hayakawa T., Kikuchi H., Abe T.:Thrombolytic therapy in embolic and thrombotic cerebral infarction: a cooperative study. In Hacke W., Del Zoppo G.J., Hirschberg (Eds.)Thrombolytic Therapy in Acute Ischemic Stroke. Springer-Verlag Berlin Heidelberg, pp. 168–171, 1991.Google Scholar
  127. [127]
    Yamaguchi T., Hayakawa T., Kikuchi H., Abe T.:Thrombolytic therapy in embolic and thrombotic cerebral infarction: a cooperative study. In: Hacke W., Del Zoppo G.J., Hirschberg (eds.) Thrombolytic Therapy in Acute Ischemic Stroke. Springer-Verlag Berlin Heidelberg, pp. 172–174, 1991.Google Scholar
  128. [128]
    Yamaguchi T., Hayakawa T., Kikuchi H. for the JapaneseThrombolysis Study Group:Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc. Dis. 3: 269–272, 1993.Google Scholar
  129. [129]
    Yusuf S., Collins R., Peto R. et al.:Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effect from 33 randomized controlled trials. Eur. Heart. J. 6: 556–585, 1985.PubMedGoogle Scholar
  130. [130]
    Zeumer H., Ringelstein E.B., Hassel M., Poeck K.: Lokale Fibrinolysetherapie bei sub totaler Stenose der a. cerebri media. Dtsch Med. Wschr., 108: 1103–1105, 1983.PubMedGoogle Scholar
  131. [131]
    Zeumer H., Hacke W., Kolmann H.L., Poeck K.: Lokale Fibrinolysetherapia bei basilaris-Thrombose. Dtsch Med. Wschr, 107: 728–731, 1982.PubMedGoogle Scholar
  132. [132]
    Zeumer H., Hacke W., Ringelstein E.B.:Local intraarterial thrombolysis in vertebrobasilar thromboembolic disease. AJNR, 4: 401–404, 1983.PubMedGoogle Scholar
  133. [133]
    Zeumer H.:Vascular recanalizing techniques in interventional neuroradiology. J. Neurol. 231: 287–294, 1985.PubMedGoogle Scholar
  134. [134]
    Zivin J.A., Fisher M., De Girolami U., Hemenway C.C., Stashak J.A.:Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science, 230: 1289–1292, 1985.PubMedGoogle Scholar

Copyright information

© Masson S.p.A. 1996

Authors and Affiliations

  • Candelise L. 
    • 1
  • Roncaglioni C. 
    • 2
  • Aritzu E. 
    • 1
  • Ciccone A. 
    • 1
  • Maggioni A. P. 
    • 2
  • the MAST-I Group
  1. 1.Istituto di Clinica NeurologicaUniversità degli Studi di MilanoMilanoItaly
  2. 2.Istituto di Ricerche Farmacologiche Mario NegriMilanoItaly

Personalised recommendations